Researchers Show Testing For Drug-Resistant Bacteria Before Prostate Biopsies Reduces Risk of Infections

Researchers Show Testing For Drug-Resistant Bacteria Before Prostate Biopsies Reduces Risk of Infections
A group of researchers from Rhode Island Hospital published their latest results in the journal Urology, whereby they show that certain infections occurring after prostate biopsy resulting from drug-resistant Escherichia coli can be prevented through rectal swab cultures before the surgery. These bacterial cultures allow the detection of antibiotic resistant E. coli and can help to select antimicrobial prophylaxis used for the surgery. However, in men who undergo transrectal ultrasound (TRUS)-guided biopsies, ciprofloxacin, a commonly used antibiotic, is probably not the best prophylactic choice for patients who test positive for ciprofloxacin-resistant E. coli. “Aware of the increasing number of resistant strains of E. coli, our urologic physicians sought to decrease the number of post-biopsy infections and readmissions by conducting cultures on patient fecal samples to identify antibiotic-resistant strains before the biopsy is done, and the results were used to make the best antibiotic choice for prophylaxis,” Leonard Mermel, DO, medical director of the department of epidemiology and infection control at Rhode Island Hospital said in a news release. “As effective as biopsies are for diagnosing cancer, they do carry some risk of infection.” There are roughly 1 million prostate biopsies preformed every year in the U.S, with approximately 200,000 cases resulting in prostate cancer diagnosis. The majority of post-biopsy infections are triggered by E. coli as a result of bacterial inoculation from the rectal mucosa directly into the urinary tract. Overall, there is a 2 to 6% rate of post-biopsy infections, with a 6.3% rate of hospital readmissions. The research team evaluated the frequency of fluoroquinolone resistance in E. coli of adult
Subscribe or to access all post and page content.